Drug Database
GR

grass pollen vaccine (DepiQuick)

✓ Approved

Laboratorios LETI · therapeutic agent

What is grass pollen vaccine?

grass pollen vaccine is a therapeutic agent developed by Laboratorios LETI. It is approved for therapeutic indications via injectable (others) or oral (po) or subcutaneous injection or sublingual (sl)/oral transmucosal.

Drug Profile

Brand NamesDepiQuick
CompanyLaboratorios LETI
RouteInjectable (Others), Oral (PO), Subcutaneous Injection, Sublingual (SL)/Oral Transmucosal
StatusApproved

Therapeutic Indications

grass pollen vaccine is developed for 3 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved
Immune system disordersHypersensitivity✓ Approved
Immune system disordersSeasonal allergy✓ Approved

Related Research Articles

PubMedAllergologie select2026-11-11

Rare allergen sources are clinically relevant sensitizers in Central Europe.

Wöhrl Julia J, Hemmer Wolfgang W, Lang Roland R, Moritz Katharina K et al.

In recent times, diagnosing allergies apart from house dust mite (HDM), birch tree, and grass pollen has become increasingly difficult because allergen manufacturers have withdrawn many commercial skin prick test (SPT) solutions for rare allergen sources. A cohort of 5,857 patients (mean age 35.9 ± 20.3 years, 60.5% female) was tested with standardized SPT panels comprising 46 inhalant and food allergens at a large allergy outpatient clinic in Vienna. Cases with positive tests and allergen-specific history were judged as "relevant", those without as "latent". In the patient cohort, 48.8% presented with a history of allergic rhinoconjunctivitis (ARC), 16.7% with bronchial asthma (BA), 13.2% with atopic dermatitis (AD), and 28.9% with food allergy (FA). Of 113,893 SPTs, 7.0% were relevant, 5.3% were latent, and 87.7% remained negative. The 3 most frequent allergen sources - grass, birch, and HDM - showed the highest ratio of 22.2% relevant compared to 7.1% latent SPTs. The 6 other non-rare allergen sources - European ash tree, mugwort, ragweed, Alternaria alternata, cat, and dog - yielded 9.5% positive and 7.4% latent SPT results. The other 34 rare allergen sources resulted in 1.8% positive and 3.9% latent tests. Plantain, horse, hazelnut (food), soymilk, peanut, plane tree, and nettle ranked top among the rare allergens. Among rare allergens, relevant SPTs to horse/rabbit, Alternaria alternata, oat flour, and rye flour were associated with an increased risk for BA including work-related asthma. 15.4% (1,230/7,985) of all relevant SPTs were observed in "rare allergens". This demonstrates the necessity of including rare allergens in standard allergy workups.

PubMedPlant cell reports2026-11-11

Combining pollen lethality and seed visual screening approaches to generate transgene-free edits in Arabidopsis thaliana.

He Minggui M, Liu Jin-Lei JL, Fu Yuwei Y, Su Yiyuan Y et al.

PubMedBiology letters2026-11-11

Sparse gut microbiomes in solitary bees and wasps.

Saiyawong Jennifer N Schlauch JNS, Watrous Kristal M KM, Buchmann Stephen S, Melin Annalie A et al.

Bees and wasps are ecologically vital, but many species are declining owing to anthropogenic stressors. Social bees harbour host-specific and dense gut microbiomes that affect their resilience to stress. However, there are tens of thousands of other bee and wasp species that vary in sociality and diet (including pollen-feeding and predatory guilds), traits known to influence host-microbe symbioses. The role of gut microbes in the biology of these species is largely unknown. Here, we measured the composition and absolute abundance of bacterial communities in adult metasomas across 61 genera and 14 families of field-collected bees, predatory wasps and pollen wasps. We found that solitary bees and both wasp guilds harbour distinct bacterial taxa and lower bacterial abundances as compared with social bees. Bacterial abundances also varied extensively among and within genera of solitary bees, with little variation explained by body size, diet breadth or nesting ecology. Furthermore, microbiome composition was only weakly differentiated among solitary bees and the two wasp groups, even when comparing herbivorous (pollen-feeding) and omnivorous taxa. We suggest that the sparse and somewhat stochastic microbiomes of solitary bees and wasps reflect weak host dependence on microbially mediated functions, a trait that may influence their responses to environmental change.

PubMedNPJ vaccines2026-11-11

A structure-guided trivalent subunit vaccine confers maternal protection to neonatal piglets against PEDV and PDCoV.

Liu Jia J, Chen Longping L, Li Dan D, Wang Zhuo Z et al.

Antigenic divergence among porcine epidemic diarrhea virus (PEDV) genotypes and porcine deltacoronavirus (PDCoV) limits the cross-protection provided by current commercial vaccines. Here, employing a structure-guided antigen design strategy, we developed a trivalent subunit vaccine concurrently targeting PEDV G2a, PEDV G2b, and PDCoV. The vaccine antigen set comprises optimized spike ectodomain antigens, featuring stabilizing mutations, a heptad repeat 2 (HR2) deletion, a fused neutralizing epitope, and a flagellin adjuvant fused to the N-terminus. Formulated with MF59+CpG adjuvants, this trivalent vaccine elicited robust PEDV- and PDCoV-specific neutralizing antibody responses and Th1/Th2-associated cellular immune responses characterized by IFN-γ, IL-2, and IL-4 production in mice. Immunization of pregnant sows with 300 μg dose induced high-titer IgG, IgA, and colostral secretory IgA (SIgA) against all three target viruses. Although neutralizing antibody titers were comparable between the 100 μg and 300 μg dose groups, the 300 μg group showed higher and more persistent levels of colostral binding IgG and SIgA. Following maternal immunization, piglets that acquired maternal antibodies through colostrum exhibited reduced clinical diarrhea, lower fecal viral RNA shedding, and less severe intestinal lesions after challenge with PEDV G2a, PEDV G2b, or PDCoV. These findings support this structure-guided trivalent subunit vaccine as a promising candidate for maternal immunization against co-circulating porcine enteric coronaviruses.

PubMedHealth communication2026-11-11

Spiritual Health Locus of Control and COVID-19 Booster Intentions Among Hispanic Americans: A Culturally Grounded Extension of the Extended Parallel Process Model.

Kim Joon J, Jun Jungmi J, Zambrano Rodriguez Viviana Carolina VC

Declining uptake of COVID-19 boosters poses significant public health concerns. Hispanic Americans, who have experienced disproportionate pandemic impacts, report lower uptake of updated boosters than non-Hispanic White adults, partly attributable to vaccine hesitancy. Although religiosity plays a central role in Hispanic communities, little is known about how spiritually grounded beliefs shape cognitive and emotional responses to vaccination. This study integrates the extended parallel process model (EPPM) with spiritual health locus of control (SHLOC) to examine how exposure to faith-based and governmental vaccine information influences booster intention through spiritually grounded efficacy appraisals. Using an online survey of Hispanic American adults (N = 349), we tested a structural equation model linking SHLOC, perceived threat, efficacy beliefs, fear, and vaccination intentions. Results indicated that active SHLOC, reflecting beliefs in divine partnership in health, increased response efficacy and indirectly promoted booster intention and vaccine advocacy, whereas passive SHLOC, reflecting divine determinism, reduced self-efficacy and indirectly discouraged booster intention. Perceived threat was positively associated with fear, and efficacy beliefs emerged as the strongest predictors of booster intention. Mediation analyses supported serial pathways from message exposure to SHLOC to efficacy to intention, identifying spiritually grounded control beliefs as a culturally embedded mechanism in vaccine decision making. Findings suggest that faith-based engagement can function as either a protective or risk communication channel, depending on whether messages reinforce divine partnership or determinism. The study advances EPPM by identifying SHLOC as a culturally grounded antecedent to efficacy appraisal and offers implications for culturally responsive vaccine communication in Hispanic communities.

PubMedInternational journal for equity in health2026-11-11

Reaching zero-dose children through the Big Catch-Up initiative in the Eastern Mediterranean Region.

Elmahdy Eman E, Mere Osama O, Farrukh Saadia S, Alyousfi Mohamad Nihad MN et al.

Routine immunization (RI) is one of the most effective public health interventions for reducing childhood morbidity and mortality. However, recent disruptions to RI have created immunity gaps in the Eastern Mediterranean Region (EMR), increasing the number of zero-dose (ZD) and under-immunized children, particularly in countries affected by conflict, displacement, service disruption, and ongoing vaccine-preventable disease outbreaks. The Big Catch-Up (BCU) initiative aimed to identify and vaccinate missed children, close immunity gaps, and strengthen RI systems. In the six Gavi-supported EMR countries included in this study (Afghanistan, Pakistan, Somalia, Sudan, Syria, and Yemen), implementation targeted children aged 12-59 months. This study assessed progress in reaching ZD children during BCU implementation in these six countries. A descriptive, multi-country programmatic analysis was conducted using quantitative and qualitative data from BCU quarterly reports covering implementation from Q4 2024 to Q1 2026. Additional data sources included World health Organization (WHO and United Nations Children's Fund (UNICEF) Estimates of National Immunization Coverage (WUENIC), Gavi-approved vaccine dose data, and UNICEF vaccine shipment data. Quantitative analysis summarized administered doses, zero-dose targets, BCU coverage, vaccine consumption, and performance by country and antigen among children aged 12-59 months. Age-disaggregated analyses were conducted for children aged 12-23 months and 24-59 months. Qualitative information from country reports on implementation successes, challenges, and lessons learned was summarized by country and thematic area. During the BCU implementation period, 3.5 million zero-dose children were reached with Penta1 across the six countries, representing 53% of the estimated cumulative population of 6.6 million ZD children. Of the 57 million Gavi-approved vaccine doses, 98% were shipped to countries, and 47.7 million doses were administered, equivalent to 84% of approved doses. Implementation success was supported by targeted identification of areas with high numbers of zero-dose children, integrated outreach, integration with other health services, and recruitment of vaccinators and deployment of community health workers. Key challenges included insecurity, population movement, inaccessible districts, community refusal, and limited community engagement. Substantial progress in reaching missed children was reported during BCU implementation in high-priority EMR countries. Lessons learned highlight the importance of integrating catch-up vaccination with RI, strengthening microplanning, ensuring timely vaccine supply and financing, improving community engagement, and institutionalizing catch-up vaccination.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about grass pollen vaccine